张军

发布时间:2011-08-04         浏览次数:7015

Jun Zhang 张军(教授博导).

Professor Jun Zhang got his Bachelor degree on Medicine in 1994 inShanghai Medical School, and then he received three years’ training onepidemiology and was awarded with master degree in 1997. After then he workedin Xiamen University as faculty until now. In 2005, he and his colleaguesfounded National Institute of Diagnostics and Vaccine Development in infectiousdiseases (NIDVD) in Xiamen University. His researches focus on the virology,immunology and epidemiology of many human pathogens. As one of the leadingscientists, he is deeply involved in the innovation and translation of therecombinant hepatitis E vaccine, the recombinant HPV 16/18 bivalent vaccine,the recombinant HPV 6/11 bivalent vaccine and many immunologic diagnosticreagents against infectious pathogens. Among them, the Hepatitis E vaccine hasbeen commercially launched in China in 2012; the HPV16/18 vaccine and HPV 6/11vaccine are under Phase III and Phase I clinical trials in China, respectively;more than 40 kinds of immunodiagnostic kits for infectious disease such asAIDS, tuberculosis, hepatitis, influenza, foot and mouth disease had beenmarketed in China. He had published > 60 papers in peer reviewed journals.

 1994年上海医科大学医学学士(预防医学专业)、1997年上海医科大学医学硕士(流行病学专业)。1997年至今任职于厦门大学,2006年晋升教授,2008年起担任博士生导师,现任厦门大学公共卫生学院副院长、国家传染病诊断试剂与疫苗工程技术研究中心副主任。2005年入选教育部新世纪优秀人才;2008年获“中国十大杰出青年”提名奖;2010年获“中国青年五四奖章”;2011年获第十二届中国青年科技奖;2012年入选科技部首批中青年科技创新领军人才,2014年入选中组部“万人计划”第一批科技创新领军人才、福建省委组织部首批特支计划“双百人才”、福建省百千万人才工程。中华医学会微免分会第八届青年委员会副主任委员,全国专业计量技术委员会委员。

 长期从事体外诊断试剂、疫苗研究,先后在《新英格兰医学杂志》、《柳叶刀》等国际学术刊物发表论文90余篇,获得国内外发明专利授权二十余项。参与研制出世界上第一个戊型肝炎疫苗和40余种体外诊断试剂并均已上市销售,研制的国内第一个宫颈癌疫苗正在进行三期临床试验。先后主持863计划重大项目等国家级重大重点科研项目十余项。先后获国家科技进步二等奖(2001,2完成人)、国家技术发明二等奖(2010,4完成人)、教育部提名国家科技进步二等奖(第1完成人)等科技奖励。

Selected Publication:

1. Jun Zhang*#, Xue-Feng Zhang#, Shou-Jie Huang, Ting Wu, Yue-Mei Hu,Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-HuiLiu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan,Yi-Min Li, J. Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu, Ning-Shao Xia*.Longer-Term Efficacy of a Vaccine against Hepatitis E. New Engl J Med 2015;372(10):914-22. (#共第一作者*共通讯作者) IF= 54.420

2. Zhu FC#,Zhang J#, ZhangXF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, AiX, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW,Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthyadults: a large-scale, randomised, double-blind placebo-controlled, phase 3trial. Lancet, 2010, 376(9744): 895–902. (#共第一作者)IF=33.633

3. Quan Yuan, Liu-WeiSong, Chun-Jen Liu, Zhuo Li, Ping-Guo Liu, Cheng-Hao Huang, Yan Yan,Sheng-Xiang Ge, Ying-Bin Wang, Cheng-Yuan Peng, Jun Zhang*, Jia-Horng Kao, Ding-Shinn Chen, Pei-Jer Chen*,Ning-Shao Xia*. Hepatitis B core antibody level may help predict treatmentresponse in chronic hepatitis B patients. Gut, 2013,62(1):182-4.(共通讯作者)(IF=10.614)

4. Huang CH, Yuan Q,Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, GeSX, Zhang J*, Xia NS*.Influence of Mutations in Hepatitis B Virus Surface Protein on ViralAntigenicity and Phenotype in Occult HBV Strains from Blood Donors. JHepatol. 2012,57(4):720-9.共通讯作者(IF=9.334)

5. Zhang J#, Zhang XF#,Zhou C, Wang ZZ, Huang SJ, Yao X, Liang ZL, Wu T, Li JX, Yan Q, Yang CL, JiangHM, Huang HJ, Xian YL, J W-K Shih, M-H Ng, Li YM , Wang JZ*, Zhu FC* and XiaNS*: Protection against hepatitis E virus infection by naturally acquired and vaccine-inducedimmunity. Clin Microbiol Infect2014; 20: O397–O405. #共第一作者(IF= 5.197)

6. Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z,Fang Y, Zhu FC, Wu T*, Zhang J*, Xia NS. Modeling the long-termantibody response of a hepatitis E vaccine. Vaccine. 2015, pii: S0264-410X(15)00839-7. doi:10.1016/j.vaccine.2015.06.050. (IF=3.492)共通讯作者

7. Wu T, Hu YM*, Li J, Chu K, Huang SJ, ZhaoH, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW,Wang Y, Zhu FC, Li CG, Zhang J*, Xia NS. Immunogenicity andsafety of an E. coli-produced bivalent human papillomavirus (type 16 and 18)vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 2015, 33(32):3940-6.共通讯作者(IF=3.492)

8. Yue Zhang, Min Li, Fan Yang, Yufang Li,Zizheng Zheng, Xiao Zhang, Qingshan Lin, Ying Wang, Shaowei Li, Ningshao Xia, JunZhang*, and Qinjian Zhao*. Comparable quality attributes of hepatitis E vaccine antigen with andwithout adjuvant adsorption-dissolution treatment. Hum Vaccin Immunother. 2015,11(5): 1129-39共通讯作者)(IF= 2.131

9. Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ,Yang CL, Cai JP, Jiang HM, Wang YJ, Guo M, Liu XH, Huang HJ, Zhu FC, ZhangJ*, Xia NS. Safety of an Escherichia coli-expressed bivalent humanpapillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-labelphase I clinical trial. Hum VaccinImmunother. 2014;10(2):1-7.通讯作者)(IF= 2.131

10. Yixin Chen, Chuan Li, Delei He, TongCheng, Shengxiang Ge, James Wai-Kuo Shih,Qinjian Zhao, Pei-Jer Chen, JunZhang, NingshaoXia, Antigenic analysis of divergentgenotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonalantibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine 2013, 31:425-430 (共通讯作者) (IF=3.492)

11. Zhang J, Shih JW*, Wu T, Li SW, Xia NS: Development of the hepatitis E vaccine:from bench to field. Sem Liver Dis2013, 33(1):79-88. (IF=8.274)

12. Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS. HepatitisE virus: neutralizing sites, diagnosis,and protective immunity. Rev Med Virol.2012,22(5):339-49.(IF=7.615)

13. Huang SJ, ZhangXF, Jiang HM, Yan Q, Ai X, Wang YJ, Cai JP, Jiang L, Wu T, Wang ZZ, Guan L,Shih JWK, Ng MH, Zhu FC, Zhang J*,Xia NS. Profile of Acute Infectious Markers in Sporadic Hepatitis E. PLoSOne. 2010, 5(10): e13560.通讯作者(IF=4.411)

14. Yu H, Yuan Q, GeSX, Wang HY, Zhang YL, Chen QR, ZhangJ*, Chen PJ, Xia NS. Molecular and phylogenetic Analyses Suggest anAdditional Hepatitis B Virus Genotype “I”, PLoS One. 2010, 5(2):e9297.通讯作者(IF=4.411)

15. Yuan Q, Ou SH,Chen CR*, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AET, ShihJWK, Zhang J*, Xia NS.Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors inSoutheast China, J Clin Microbiol, 2010, 48: 357–362. 共通讯作者)(IF=4.220

16. Zhu FC, Huang SJ,Wu T, Zhang XF, Wang ZZ, Ai X, Yan Q, Yang CL, Cai JP, Jiang HM, Wang YJ,Mun-Hon Ng, Zhang J *, XiaNS. Epidemiology of Zoonotic Hepatitis E: A Community-Based Surveillance Studyin a Rural Population in China. PLoS One, 2014, 9(1): e87154 通讯作者)(IF=3.534

17. Li A, Yuan Q,Huang ZY, Fan J, Guo RY, Lou B, Zheng Q, Ge SX*, Chen YX, Su ZJ, Yeo AET, ChenY, Zhang J*, Xia NS. NovelDouble-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody. ClinVac Immunol 2010,17:464–469.(共通讯作者)(IF =2.471

18. Yuan Q, Ge SX,Xiong JH, Yan Q, Li Z, Hao XK, Tian DY, Niu JJ, Su ZJ, Chen CR, Shih JWK, Zhang J,Xia NS. A novel immunoassay for PreS1 and/or core-related antigens fordetection of HBsAg variants. J Virol Methods.2010;168(1-2):108-113.通讯作者)(IF =2.139

19. Zhang J, Liu CB, Li RC, LiYM, Zheng YJ, Li YP, Luo D, Pan BB, Nong Y, Ge SX, Xiong JH, Shih JW, Ng MH,Xia NS. (2009) Randomized-controlled phase II clinical trial of a bacteriallyexpressed recombinant hepatitis E vaccine. Vaccine, 27:1869-1874 (IF =3.377)

20. Wu T., Wu X.L., OuS.H., Lin C.X., Cheng T., Li S.W., Ng M.H., Zhang J.,*XiaN.S.*, Difference of T cell and B cell activation in two homologousproteins with similar antigenicity but great distinct immunogenicity. MolImmunol, 2007, 44(12): 3261-3266(IF =3.742)共通讯作者

21. Zhang J, Gu Y, Ge SX, LiSW, He ZQ, Huang GY, Zhuang H, Ng MH, Xia NS. Analysis of hepatitis E virusneutralization sites using monoclonal antibodies directed against a viruscapsid protein. Vaccine 2005;23:2881-2892 (IF =3.377)

22. Zhang J, Ge SX, Huang GY,Li SW, He ZQ, Wang YB, Zheng YJ, Gu Y, Ng MH, Xia NS. Evaluation ofantibody-based and nucleic acid-based assays for diagnosis of hepatitis E virusinfection in a rhesus monkey model. J Med Virol 2003;71:518-526  (IF =2.471).